

## CURRICULUM VITAE

**Date of Revision: 04/20/ 2024**

**Name: Atieh Amouzegar**

**Education:** *(Start with the first academic degree according to date; from past to present)*

1. 1998. Medical doctor. Iran University of Medical Sciences, Tehran Iran Year of Graduation.
2. 2004. Specialty of Internal Medicine .Tehran University of medical science, Tehran Iran
3. 2007. Sub specialty of endocrinology and metabolism Shahid Beheshti University of medical science, Tehran Iran

**Career/Academic Appointments:** *(Academic positions should be listed by date from past to present )*

1. 2007-2012- Faculty member, Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshi University of Medical Sciences, Tehran, Iran (2007-2012).
2. 2012 to now- Faculty member (Director), Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshi University of Medical Sciences, Tehran, Iran (2012-2024).

**Administrative Positions:** *(Administrative position should be listed by date from past to present )*

1. 2012 to now- Director: Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran (2012-2024).

**Professional Honors & Recognition:** *(Scientific Awards, incentives and obtained scientific points should be mentioned by date from past to present)*

1. 2007- Second rank of National Board of Endocrinology
2. 2014- Outstanding Researcher in Endocrinology and Metabolism (Avicenna Prize) in 14th
3. 2018- Distinguished Associate Professor in 9th- Festival of Shahid Beheshti University of Medical Sciences
4. 2023- First rank of academy of medical sciences

[Type here]

**Grant History:** *(If you have national or international grants, mention them by date from past to present)*

**Completed Grants:** *(If you have any national or international completed grants, mention them by date from past to present)*

**Lectures, Courses, Web-based Education:** *(If you have presented or participated in any lecture, educational courses or web-based education, during the last 5 years mention their subject or title)*

2024: Web-based Education in the field of thyroid disorders and diabetes

**Journal Service:** *(Membership in the editorial board, being a journal director, chief editor or the journal reviewing board or any related position)*

1. 2013 to now- Associate Editor of International Journal of Endocrinology & Metabolism

**Professional Organizations:** *(Membership in the Professional and specific Organizations)*

1. 2012 to now- Member of Iran Endocrine Society

**Committees Memberships:** *(Membership in university committees such as ethics committee in research and other professional committees)*

Member of Iran Endocrine Society (**Since 2012**)

**Bibliography:**

**Peer-Reviewed Original Research :** *( List of published articles according to Vancouver style, from past to present)*

**2011:**

1. Azizi F, Amouzegar A. Eur J Endocrinol. Management of hyperthyroidism during pregnancy and lactation. 2011 Jun; 164(6):871-6.

2. Azizi F, Hosseini MS, Amouzegar A, Tohidi M, Ainy E. Neonatal thyroid status in an area of iodine sufficiency. J Endocrinol Invest. 2011 Mar; 34(3):197-200.

3. Ghazi AA, Boustani I, Amouzegar A, Attarian H, Pourafkari M, Gashti HN, Sabetian T, Tirgari F, Ghazi S, Kovacs K. Postpartum hypercalcemia secondary to a neuroendocrine tumor of pancreas; a case report and review of literature. Iran J Med Sci. 2011 Sep; 36(3):217-21.

**2012:**

4. Mehran L, Amouzegar A, Delshad H, Azizi F. Association between serum TSH concentration and body mass index in euthyroid subjects: the role of smoking. Arch Iran Med. 2012 Jul; 15(7):400-3.

[Type here]

5. Delshad H, Amouzegar A, Mirmiran P, Mehran L, Azizi F. Eighteen years of continuously sustained elimination of iodine deficiency in the Islamic Republic of Iran: the vitality of periodic monitoring. *Thyroid*. 2012 Apr; 22(4):415-21.
6. Mehran L, Amouzegar A, Delshad H, Azizi F. The association of cigarette smoking with serum TSH concentration and thyroperoxidase antibody. *Exp Clin Endocrinol Diabetes*. 2012 Feb; 120(2):80-3.
7. Zadeh-Vakili A, Ramezani Tehrani F, Hashemi S, Amouzegar A, Azizi F. Relationship between Sex Hormone Binding Globulin, Thyroid Stimulating Hormone, Prolactin and Serum Androgens with Metabolic Syndrome Parameters in Iranian Women of Reproductive Age. *Diabetes Metab* 2012; S2-008.
8. Sabet Z, Azizi F, Amouzegar A. Serum testosterone, free testosterone index and SHBG concentration for reduction of metabolic syndrome in Tehranian men. *Endocrine Care* 2012; VIII: 453-466.

### **2013:**

9. Amouzegar A, Azizi F. Hormones (Athens). Variations of urinary iodine during the first trimester of pregnancy in an iodine-replete area. Comparison with non-pregnant women. 2013 Jan-Mar; 12(1):111-8.
10. Fam B, Amouzegar A, Arzhan S, Ghanbariyan A, Delshad M, Hosseinpanah F, Azizi F. Association between Physical Activity and Metabolic Risk Factors in Adolescents: Tehran Lipid and Glucose Study. *Int J Prev Med*. 2013 Sep; 4(9):1011-7.
11. Amouzegar A, Delshad H, Mehran L, Tohidi M, Khafaji F, Azizi F. Reference limit of thyrotropin (TSH) and free thyroxine (FT4) in thyroperoxidase positive and negative subjects: a population based study. *J Endocrinol Invest*. 2013 Dec; 36(11):950-4.
12. Mehran L, Amouzegar A, Delshad H, Askari S, Hedayati M, Amirshakari G, Azizi F. Trimester-specific reference ranges for thyroid hormones in Iranian pregnant women. *J Thyroid Res*. 2013; 2013:651517.
13. Azizi F, Amouzegar A, Delshad H, Tohidi M, Mehran L, Mehrabi Y. Natural course of thyroid disease profile in a population in nutrition transition: Tehran Thyroid Study. *Arch Iran Med*. 2013 Jul; 16(7):418-23.
14. Alamdari S, Azizi F, Delshad H, Sarvghadi F, Amouzegar A, Mehran L. Management of hyperthyroidism in pregnancy: comparison of recommendations of american thyroid association and endocrine society. *J Thyroid Res*. 2013; 2013:878467.
15. Mehran L, Tohidi M, Sarvghadi F, Delshad H, Amouzegar A, Soldin OP, Azizi F. Management of thyroid peroxidase antibody euthyroid women in pregnancy: comparison of the American thyroid association and the endocrine society guidelines. *J Thyroid Res*. 2013; 2013:542692.
16. Faam B, Hosseinpanah F, Amouzegar A, Ghanbarian A, Asghari G, Azizi F. Leisure-time physical activity and its association with metabolic risk factors in Iranian adults: Tehran Lipid and Glucose Study, 2005-2008. *Prev Chronic Dis*. 2013; 10:E36.

[Type here]

17. Azizi F, Mehran L, Amouzegar A, Delshad H, Tohidi M, Askari S, Hedayati M. Establishment of the trimester-specific reference range for free thyroxine index. *Thyroid*. 2013 Mar; 23(3):354-9.

**2014:**

18. Amouzegar A, Ainy E, Khazan M, Mehran L, Hedayati M, Azizi F. Local versus international recommended TSH references in the assessment of thyroid function during pregnancy. *Horm Metab Res*. 2014 Mar; 46(3):206-10.

19. Amouzegar A, Khazan M, Hedayati M, Azizi F. An assessment of the iodine status and the correlation between iodine nutrition and thyroid function during pregnancy in an iodine sufficient area. *Eur J Clin Nutr*. 2014 Mar; 68(3):397-400.

20. Azizi F, Amouzegar A, Mehran L, Alamdari S, Subekti I, Vaidya B, Poppe K, Sarvghadi F, Luis Jr TS, Akamizu T. Management of hyperthyroidism during pregnancy in Asia. *Endocr J*. 2014; 61(8):751-8.

21. Azizi F, Amouzegar A, Mehran L, Alamdari S, Subekti I, Vaidya B, Poppe K, Luis Jr TS, Akamizu T. Screening and management of hypothyroidism in pregnancy: Results of an Asian survey. *Endocr J*. 2014; 61(7):697-704.

22. Amouzegar A, Beigy M, Gharibzadeh S, Azizi F. Underestimation of Thyroid Dysfunction Risk Due to Regression Dilution Bias in a Long-Term Follow-Up: Tehran Thyroid Study (TTS). *Horm Metab Res*. 2014 Jun; 46(6):440-4.

23. Khazan M, Amouzegar A, Gharibzadeh S, Mehran L, Tohidi M, Azizi F. Prevalence of hypothyroidism in patients with dyslipidemia: Tehran Thyroid Study (TTS). *Horm Metab Res*. 2014 Dec; 46(13):980-4.

24. Delshad H, Amouzegar A, Mehran L, Azizi F. Comparison of two guidelines on management of thyroid nodules and thyroid cancer during pregnancy. *Arch Iran Med*. 2014 Oct; 17(10):670-3.

25. Amouzegar A, Mehran L, Sarvghadi F, Delshad H, Azizi F, Lazarus JH. Comparison of the American Thyroid Association with the Endocrine Society practice guidelines for the screening and treatment of hypothyroidism during pregnancy. *Hormones (Athens)*. 2014 Jul-Sep; 13(3):307-13.

26. Mehran L, Amouzegar A, Tohidi M, Moayedi M, Azizi F. Serum free thyroxine concentration is associated with metabolic syndrome in euthyroid subjects. *Thyroid*. 2014 Nov; 24(11):1566-74.

[Type here]

**2015:**

27. Amouzegar A, Kazemian E, Gharibzadeh S, Mehran L, Tohidi M, Azizi F. Association between thyroid hormones, thyroid antibodies and insulin resistance in euthyroid individuals: A population-based cohort. *Diabetes Metab.* 2015 Dec; 41(6):480-8.

[Type here]

**2016:**

28. Azizi F, Mehran L, Amouzegar A, Alamdari S, Subetki I, Saadat N, Moini S, Sarvghadi F. Prevalent Practices of Thyroid Diseases During Pregnancy Among Endocrinologists, Internists and General Practitioners. *Int J Endocrinol Metab*. 2015 Nov 7; 14(1):e29601. doi: 10.5812/ijem.29601. eCollection 2016 Jan.
29. Amouzegar A, Bakhtiyari M, Mansournia MA, Etemadi A, Mehran L, Tohidi M, Azizi F. Sex and age specific reference values and cut-off points for TPOAb: Tehran Thyroid Study (TTS). *Thyroid*. 2016 Mar; 26(3):458-65.
30. Amouzegar A, Heidari M, Gharibzadeh S, Mehran L, Tohidi M, Azizi F. The Association between Blood Pressure and Normal Range Thyroid Function Tests in a Population Based Tehran Thyroid Study. *Horm Metab Res*. 2016 Mar; 48(3):151-6.
31. Malek M, Esfahanian F, Amouzegar A, Sarvghadi F, Moossavi Z, Mohajeri-Tehrani MR, Khamseh ME, Amirbaigloo A, Ebrahim Valojerdi A. A survey of clinical practice patterns in diagnosis and management of Cushing's disease in Iran. *Med J Islam Repub Iran*. 2016 Feb 21;30:334. eCollection 2016.
32. Ghannadi S, Amouzegar A, Amiri P, Karbalaefar R, Tahmasebinejad Z, Kazempour-Ardebili S. Evaluating the Effect of Knowledge, Attitude, and Practice on Self-Management in Type 2 Diabetic Patients on Dialysis. *J Diabetes Res*. 2016:3730875.
33. Ramezani Tehrani F, Bahri Khomami M, Amouzegar A, Azizi F. Thyroperoxidase antibodies and polycystic ovarian morphology. *Int J Gynaecol Obstet*. 2016 Aug;134(2):197-201
34. Bagheripuor F, Gharibzadeh S, Ghanbari M, Amouzegar A, Tohidi M, Azizi F, Ghasemi A. Association between serum nitric oxide metabolites and thyroid hormones in a general population: Tehran Thyroid Study. *Endocr Res*. 2016 Aug;41(3):193-9.
35. Gharibzadeh S, Mohammad K, Rahimiforoushani A, Amouzegar A, Mansournia MA. Standardization as a Tool for Causal Inference in Medical Research. *Arch Iran Med*. 2016 Sep;19(9):666-670.
36. Karbalaefar R, Kazempour-Ardebili S, Amiri P, Ghannadi S, Tahmasebinejad Z, Amouzegar A. Evaluating the effect of knowledge, attitude and practice on self-management in patients with type 2 diabetes. *Acta Diabetol*. *Acta Diabetol*. 2016 Dec;53(6):1015-1023.
37. Alamdari SH, Amouzegar A, Tohidi M, Gharibzadeh S, Kheirkhah P, Kheirkhah P, Azizi F. Hypothyroidism and Lipid Levels in a Community Based Study (TTS). *International Journal of Endocrinology and Metabolism*. *Int J Endocrinol Metab*. 2016Jan; 14(1):e22827.

[Type here]

## **2017:**

38. Amouzegar A, Mehran L, Hasheminia M, Kheirkhah Rahimabad P, Azizi F. The predictive value of metabolic syndrome for cardiovascular and all-cause mortality: Tehran Lipid and Glucose Study. *Diabetes Metab Res Rev*. 2017 Jan; 33(1).
39. Daneshpour MS, Fallah MS, Sedaghati-Khayat B, Guity K, Khalili D, Hedayati M, Ebrahimi A, Hajsheikholeslami F, Mirmiran P, Ramezani Tehrani F, Momenan AA, Ghanbarian A, Amouzegar A, Amiri P, Azizi F.N. Rationale and Design of a Genetic Study on Cardiometabolic Risk Factors: Protocol for the Tehran Cardiometabolic Genetic Study (TCGS). *JMIR Res Protoc*. 2017 Feb 23;6(2):e28.
40. Amouzegar A, Gharibzadeh S, Kazemian E, Mehran L, Tohidi M, Azizi F. The Prevalence, Incidence and Natural Course of Positive Antithyroperoxidase Antibodies in a Population-Based Study: Tehran Thyroid Study. *PLoS One*. 2017 Jan 4;12(1):e0169283.
41. Amouzegar A, Ghaemmaghami Z, Beygi M, Gharibzadeh S, Mehran L, Tohidi M, Azizi F. Natural course of euthyroidism and clues for early diagnosis of thyroid dysfunctions: Tehran Thyroid Study (TTS). *Thyroid*. 2017 May;27(5):616-625.
42. Amiri P, Hamzavi-Zarghani N, Nazeri P, Ghofranipour F, Karimi M, Amouzegar A, Azizi F. Can an educational intervention improve iodine nutrition status in pregnant women? A randomized controlled trial. *Thyroid*. 2017 Mar;27(3):418-425.
43. Mehran L, Amouzegar A, Rahimabad PK, Tohidi M, Tahmasebinejad Z, Azizi F. Thyroid Function and Metabolic Syndrome: A Population-Based Thyroid Study. *Horm Metab Res*. 2017 Mar;49(3):192-200.
44. Amiri P, Asghari G, Sadrosadat H, Karimi M, Amouzegar A, Mirmiran P, Azizi F. Psychometric Properties of a Developed Questionnaire to Assess Knowledge, Attitude and Practice Regarding Vitamin D (D-KAP-38). 2017 May 8;9(5). pii: E471.
45. Ahi S, Amouzegar A, Gharibzadeh S, Kazempour-Ardebili S, Delshad H, Tohidi M, Azizi F. The Association Between Normal Range TSH and Lipid Profile. *Horm Metab Res*. 2017 Jun;49(6):424-429. doi: 10.1055/s-0043-110142. Epub 2017 Jun 8.
46. Talaei B, Amouzegar A, Sahranavard S, Hedayati M, Mirmiran P, Azizi F. Effects of Cinnamon Consumption on Glycemic Indicators, Advanced Glycation End Products, and Antioxidant Status in Type 2 Diabetic Patients. *Nutrients*. 2017 Sep 8;9(9). pii: E991.
47. Gholampour Dehaki M, Amouzegar A, Delshad H, Mehrabi Y, Tohidi M, Azizi F. Thyroid dysfunction in patients with impaired glucose metabolism: 11 year follow up from the Tehran Thyroid Study. *PLoS One*. 2017 Oct 3;12(10):e0184808.
48. Mehran L, Amouzegar A, Bakhtiyari M, Mansournia MA, Kheirkhah Rahimabad P, Tohidi M, Azizi F. Variations in serum free thyroxin concentration within normal ranges predict the incidence of metabolic syndrome in non-obese adults: a Cohort Study. *Thyroid*. 2017 Jul;27(7):886-893.

[Type here]

49. Abdi H, Kazemian E, Gharibzadeh S, Amouzegar A, Mehran L, Tohidi M, Rashvandi Z, Azizi F. Association between Thyroid Function and Body Mass Index: A 10-Year Follow-Up. *Ann Nutr Metab.* 2017;70(4):338-345.
50. Abdi H, Hosseinpanah F, Azizi F, Hadaegh F, Amouzegar A. Screening for Dysglycemia: A Comment on Classification and Diagnosis of Diabetes in American Diabetes Association Standards of Medical Care in Diabetes-2016. *Arch Iran Med.* 2017 Jun; 20(6):389.
51. Azizi F, Amouzegar A. Controversies in Management of Hyperthyroidism during Pregnancy. *Arch Iran Med.* 2017 Oct; 20(10):657-658.
52. Mehran L, Khalili D, Yarahmadi S, Amouzegar A, Mojarrad M, Ajang N, Azizi F. Worldwide Recall Rate in Newborn Screening Programs for Congenital Hypothyroidism.. *Int J Endocrinol Metab.* 2017 Jun 25;15(3):e55451.
53. Askari S, Abdi H, Ahmadi S, Bahadoran Z, Amouzegar A. Knowledge of Thyroid Disorders during Pregnancy among General Practitioners in Iran. *Int J Endocrinol Metab.* 2017 Jun 21;15(3):e55450.
54. Ghazi AA, Zadeh-Vakili A, Zarif Yeganeh M, Alamdari S, Amouzegar A, Khorsandi AA, Amirbaigloo A, Azizi F. Hereditary Vitamin D Resistant Rickets: Clinical, Laboratory, and Genetic Characteristics of 2 Iranian Siblings. *Int J Endocrinol Metab.* 2017 Jul 31;15(3):e12384.
55. Azizi F, Mehran L, Hosseinpanah F, Delshad H, Amouzegar A. Primordial and Primary Preventions of Thyroid Disease. *Int J Endocrinol Metab.* 2017 Oct 7; 15(4):e57871.
56. Khamseh ME, Mohajeri Tehrani MR, Mousavi Z, Malek M, Imani M, Hoshangian Tehrani N, Ghorbani M, Akbari H, Sarvghadi F, Amouzegar A, Esfahanian F, Hashemi Madani N, Emami Z. Iran Pituitary Tumor Registry: Description of the Program and Initial Results. *Arch Iran Med.* 2017 Dec 31;20(12):746-751.



[Type here]

## **2018:**

57. Tohidi M, Derakhshan A, Akbarpour S, Amouzegar A, Mehran L, Baghbani-Oskouei A, Azizi F, Hadaegh F. Thyroid Dysfunction States and Incident Cardiovascular Events: The Tehran Thyroid Study. *Horm Metab Res*. 2018 Jan;50(1)
58. Azizi F, Amouzegar A. Management of thyrotoxicosis in children and adolescents: 35 years' experience in 304 patients. *J Pediatr Endocrinol Metab*. 2018 Jan 26;31(2):159-165.
59. Abdi H, Gharibzadeh S, Tasdighi E, Amouzegar A, Mehran L, Tohidi M, Azizi F. Associations Between Thyroid and Blood Pressure in Euthyroid Adults: A 9-Year Longitudinal Study. *Horm Metab Res*. 2018 Mar;50(3):236-241.
60. Amouzegar A, Kazemian E, Abdi H, Mansournia MA, Bakhtiyari M, Hosseini MS, Azizi F. Association Between Thyroid Function and Development of Different Obesity Phenotypes in Euthyroid Adults: A Nine-Year Follow-Up.. *Thyroid*. 2018 Apr;28(4):458-464.
61. Abdi H, Azizi F, Amouzegar A. Insulin Monotherapy Versus Insulin Combined with Other Glucose-Lowering Agents in Type 2 Diabetes: A Narrative Review. *Int J Endocrinol Metab*. 2018 Apr 21;16(2):e65600.
62. Azizi F, Mehran L, Hosseinpanah F, Delshad H, Amouzegar A. A Secondary and tertiary preventions of thyroid disease. *Endocr Res*. 2018 May;43(2):124-140.
63. Abdi H, Amouzegar A, Tohidi M, Azizi F, Hadaegh F. Blood Pressure and Hypertension: Findings from 20 Years of the Tehran Lipid and Glucose Study (TLGS). *Int J Endocrinol Metab*. 2018 Oct 20 ;16(4 Suppl):e84769.
64. Parizadeh D, Momenan AA, Amouzegar A, Azizi F, Hadaegh F. Tobacco Smoking: Findings from 20 Years of the Tehran Lipid and Glucose Study. *Int J Endocrinol Metab*. 2018 Oct 31;16(4 Suppl):e84738.
65. Amouzegar A, Mehran L, Takyar M, Abdi H, Azizi F. Tehran Thyroid Study (TTS). *Int J Endocrinol Metab*. 2018 Oct 24; 16(4 Suppl):e84727.
66. Amiri P, Kazemian E, Mansouri-Tehrani MM, Khalili A, Amouzegar A. Does motivational interviewing improve the weight management process in adolescents? Protocol for a systematic review and meta-analysis. *Syst Rev*. 2018 Oct 30; 7(1):178.
67. Sadaie MR, Farhoudi M, Zamanlu M, Aghamohammadzadeh N, Amouzegar A, Rosenbaum RE, Thomas GA. What does the research say about androgen use and cerebrovascular events? *Ther Adv Drug Saf*. 2018 May 8;9(8):439-455.
68. Gharibzadeh S, Mansournia MA, Rahimiforoushani A, Alizadeh A, Amouzegar A, Mehrabani-Zeinabad K, Mohammad K. Comparing different propensity score estimation methods for estimating the marginal causal effect through standardization to propensity scores. *Communications in Statistics: Simulation and Computation*. 2018; 47(4): 964-976.

[Type here]

## **2019:**

69. Nodehi M, Ajami A, Izad M, Asgarian Omran H, Chahardoli R, Amouzegar A, Yekaninejad S, Hemmatabadi M, Azizi F, Esfahanian F, Mansouri F, Mazaheri Nezhad Fard R, Saboor-Yaraghi AA. Effects of vitamin D supplements on frequency of CD4+ T-cell subsets in women with Hashimoto's thyroiditis: a double-blind placebo-controlled study. *Eur J Clin Nutr*. 2019 Jan 29. doi: 10.1038/s41430-019-0395-z.
70. Mehran L, Khalili D, Yarahmadi S, Delshad H, Mehrabi Y, Amouzegar A, Ajang N, Azizi F. Evaluation of the congenital hypothyroidism screening programme in Iran: a 3-year retrospective cohort study. *Arch Dis Child Fetal Neonatal Ed*. 2019 Mar;104(2):F176-F181. doi: 10.1136/archdischild-2017-313720.
71. Azizi F, Takyar M, Madreseh E, Amouzegar A. Treatment of Toxic Multinodular Goiter: Comparison of Radioiodine and Long-Term Methimazole Treatment. *Thyroid*. 2019 May;29(5):625-630.
72. Azizi F, Takyar M, Madreseh E, Amouzegar A. Long-term Methimazole Therapy in Juvenile Graves' Disease: A Randomized Trial. *Pediatrics*. 2019 May;143(5). pii: e20183034.
73. Chahardoli R, Saboor-Yaraghi AA, Amouzegar A, Khalili D, Vakili AZ, Azizi F. Can Supplementation with Vitamin D Modify Thyroid Autoantibodies (Anti-TPO Ab, Anti-Tg Ab) and Thyroid Profile (T3, T4, TSH) in Hashimoto's Thyroiditis? A Double Blind, Randomized Clinical Trial. *Horm Metab Res*. 2019 May;51(5):296-301.
74. Ahi S, Amouzegar A, Gharibzadeh S, Delshad H, Tohidi M, Azizi F. Trend of lipid and thyroid function tests in adults without overt thyroid diseases: A cohort from Tehran thyroid study. *PLoS One*. 2019 May 16;14(5):e0216389.
75. Kazemian E, Akbari ME, Moradi N, Gharibzadeh S, Mondul AM, Jamshidi-Naeini Y, Khademolmele M, Zarins KR, Ghodoosi N, Amouzegar A, Davoodi SH, Rozek LS. Vitamin D Receptor Genetic Variation and Cancer Biomarkers among Breast Cancer Patients Supplemented with Vitamin D3: A Single-Arm Non-Randomized Before and After Trial. *Nutrients*. 2019 Jun 4;11(6). pii: E1264.
76. Keyhanian M, Sarvghadi F, Mehran L, Amouzegar A, Beigy M, Tohidi M, Azizi F. Long-Term Variations of Antithyroperoxidase Antibodies and its Clinical Significance. *Horm Metab Res*. 2019 Jun;51(6):347-352.
77. Mehran L, Yarahmadi S, Khalili D, Hedayati M, Amouzegar A, Mousapour P, Ajang N, Azizi F. Audit of the Congenital Hypothyroidism Screening Program in 15 Provinces of Iran. *Arch Iran Med*. 2019 Jun 1;22(6):310-317
78. Amiri P, Mohammadzadeh-Naziri K, Abbasi B, Cheraghi L, Jalali-Farahani S, Momenan AA, Amouzegar A, Hadaegh F, Azizi F. Smoking habits and incidence of cardiovascular diseases in men and women: findings of a 12 year follow up among an urban Eastern-Mediterranean population. *BMC Public Health*. 2019 Aug 5;19(1):1042. doi: 10.1186/s12889-019-7390-0.
79. Kazemian E, Amouzegar A, Akbari ME, Moradi N, Gharibzadeh S, Jamshidi-Naeini Y, Khademolmele M, As-Habi A, Davoodi SH. Vitamin D receptor gene polymorphisms affecting changes in visceral fat, waist

[Type here]

circumference and lipid profile in breast cancer survivors supplemented with vitamin D3. *Lipids Health Dis.* 2019 Aug 9;18(1):161. doi: 10.1186/s12944-019-1100-x.

80. Azizi F, Amouzegar A, Tohidi M, Hedayati M, Cheraghi L, Mehrabi Y. Systemic Thyroid Hormone Status in Treated Graves' Disease. *Int J Endocrinol Metab.* 2019 Oct 12;17(4):e95385. doi: 10.5812/ijem.95385. eCollection 2019 Oct.
81. Azizi F, Amouzegar A, Tohidi M, Hedayati M, Khalili D, Cheraghi L, Mehrabi Y, Takyar M. Increased remission rates after long-term methimazole therapy in patients with Graves' disease: Results of a randomized clinical trial. *Thyroid.* 2019 Sep;29(9):1192-1200. doi: 10.1089/thy.2019.0180. Epub 2019 Aug 28.
82. Azizi F, Hadaegh F, Hosseinpanah F, Mirmiran P, Amouzegar A, Abdi H, Asghari G, Parizadeh D, Montazeri SA, Lottfaliany M, Takyar F, Khalili D. Metabolic health in the Middle East and north Africa. *Lancet Diabetes Endocrinol.* 2019 Nov;7(11):866-879. doi: 10.1016/S2213-8587(19)30179-2. Epub 2019 Aug 14. Review.
83. Kazemian E, Amouzegar A, Akbari ME, Moradi N, Gharibzadeh S, Jamshidi-Naeini Y, Khademolmele M, As'habi A, Davoodi SH. Correction to: Vitamin D receptor gene polymorphisms affecting changes in visceral fat, waist circumference and lipid profile in breast cancer survivors supplemented with vitamin D3. *Lipids Health Dis.* 2019 Sep 14;18(1):174. doi: 10.1186/s12944-019-1110-8.
84. Kazemin E, Jamshidi-naeini Y, Akbari MA, Moradi N, Gharibzadeh S, Amouzegar A, Mondul A, Khademolmele M, Ghodoosi N, Zarins KR, Davoodi SH, Rozek L. Interaction Effects of Vitamin D Receptor Polymorphisms and Vitamin D3 Supplementation on Plasma Oxidative Stress and Apoptotic Biomarkers Among Breast Cancer Survivors (P05-027-19). *Curr Dev Nutr.* 2019 Jun; 3(Suppl 1): nzz030.P05-027-19. Published online 2019 Jun 13. doi: 10.1093/cdn/nzz030.P05-027-19.
85. Bahri S, Ramezani Tehrani F, Amouzegar A, Rahmati M, Tohidi M, Vasheghani V, Azizi F. Overtime trend of thyroid hormones and thyroid autoimmunity and ovarian reserve: A longitudinal population study with a 12-year follow up. *BMC Endocrine Disorders*, 2019; 19(1): 47.
86. Mehran L, Amouzegar A, Azizi F. Thyroid disease and the metabolic syndrome. *Curr Opin Endocrinol Diabetes Obes.* 2019 Oct;26(5):256-265. doi: 10.1097/MED.0000000000000500.
87. Abdi H, Amouzegar A, Azizi F. Antithyroid drugs. *Iranian Journal of Pharmaceutical Research. Iran J Pharm Res.* 2019 Autumn; 18(Suppl1): 1–12. doi: 10.22037/ijpr.2020.112892.14005

[Type here]

## **2020**

88. Kadkhodazadeh H, Amouzegar A, Mehran L, Gharibzadeh S, Azizi F, Tohidi M. Smoking status and changes in thyroid-stimulating hormone and free thyroxine levels during a decade of follow-up: The Tehran thyroid study. *Caspian J Intern Med*. 2020 Winter;11(1):47-52.
89. Kazemian E, Akbari ME, Moradi N, Gharibzadeh S, Amouzegar A, Jamshidi-Naeini Y, Mondul AM, Khademolmele M, Ghodoosi N, Zarins KR, Shateri Z, Davoodi SH, Rozek LS. Effect of vitamin D receptor polymorphisms on plasma oxidative stress and apoptotic biomarkers among breast cancer survivors supplemented vitamin D3. 2020; *European journal of cancer prevention*, 29(5): 433-444.
90. Amouzegar A , Kazemian E, Abdi H, Gharibzadeh S, Tohidi T , Azizi F . Abdominal Obesity Phenotypes and Incidence of Thyroid Autoimmunity: A 9-Year Follow-up. *Endocrine Research*.2020; 45(3): 202-209.
91. Azizi F, Amouzegar A, Mehran M, Abdi H . LT4 and slow release T3 combination: Optimum therapy for hypothyroidism? *International Journal of Endocrinology and Metabolism*, 2020; 18(2): e100870.
92. Takyar M, Rahmani M, Amouzegar A, Madreseh E, Tohidi M, Mehran L, Azizi F. Parity and incidence of thyroid autoimmunity a population-based study Tehran thyroid study (TTS).*Thyroid*. 2020 Mar 11. doi: 10.1089/thy.2019.0440.
93. Amouzegar A, Azizi F, Ashrafiavand S, Ahi Z, Saleh M, Mohaghegh S, Saleh Gargari S. Prevalence of calcium and vitamin D deficiency and their association with fetomaternal outcomes in a sample of Iranian pregnant women. *Hum Antibodies*. 2020;28(4):305-312.
94. Etemadi A, Amouzegar A, Mehran L, Tohidi M, Azizi F, Moradi K, Delshad H. Isolated Hypothyroxinemia in Iranian Pregnant Women, the Role of Iodine Deficiency: A Population-Based Cross-Sectional Study. *Thyroid*. 2020 Feb;30(2):262-269.
95. Tohidi M, Baghbani-Oskouei A, Amouzegar A, Mehran L, Azizi F, Hadaegh F. Serum Thyroid Peroxidase Antibody Level and Incident Hypertension in Iranian Men: A Suggestion for the Role of Thyroid Autoimmunity. *Endocr Metab Immune Disord Drug Targets*. 20(10), 2020.1711-1718(8)
96. Zahedi, M, Kazemian, E, Ramezani-Tehrani, F, Tohidi M, Azizi, F, Khalili D.c,d, Rahmati M.b, Amouzegar A. Assessment of the simultaneous effect of hypothyroidism and thyroid autoimmunity with gestational diabetes on the incidence of type 2 diabetes. *BMC Endocrine Disorders*. 20(1), 1 October 2020, 150.
97. Hatami H, Mahdavi M, Amouzegar A, Mehran L, Tohidi M, Azizi F. Association between Thyroid Function and Body Mass Index in Tehran Thyroid Study Population. *Iranian Journal of Endocrinology and Metabolism*. 22(4), 271 – 278.
98. Mehran L, Khalili D, Amouzegar A, Cheraghi L, Yarahmadi S, Azizi F. Determining the Prognostic Factors of Permanent Congenital Hypothyroidism. *Iranian Journal of Endocrinology and Metabolism*. 22(2), 101 – 108.

[Type here]

99. Mehrdad S.M., Amouzegar A. Hyperglycemia Management in Hospitalized Patients: A Narrative Review. Iranian Journal of Endocrinology and Metabolism. 22(3), pp. 230-251.
100. Mehran L , Amouzegar A., Gharibzadeh S, Abdi H , Mansournia MA, Tohidi M, Azizi F . Cumulative effects of thyroid hormones over 10 years and risk of general and abdominal obesity; tehran thyroid study. Horm Metab Res. 2021 May;53(5):335-340.
101. Abdi H, Amouzegar A. Management of Graves' Hyperthyroidism: More Than a Century of Progression. International Journal of Endocrinology and Metabolism 18,e103943.

[Type here]

## **2021:**

102. Azizi F, Abdi H , Cheraghi L, Amouzegar A. Treatment of subclinical hyperthyroidism in the elderly: Comparison of radioiodine and long-term methimazole treatment. *Thyroid*. 2021 Aug 18. 2021 Apr;31(4):545-551.
103. Amiri P, Mansouri-Tehrani MM , Khalili-Chelik A , Karimi M, Jalali-Farahani S, Amouzegar A, Kazemian E. Does Motivational Interviewing Improve the Weight Management Process in Adolescents? A Systematic Review and Meta-analysis. *Int J Behav Med*. 2022 Feb;29(1):78-103
104. Amouzegar A, Asgari S, Azizi F, Momenan AA, Bozorgmanesh M, Hadaegh F. The Role of Metabolic Syndrome and its Components in Incident Fracture: A 15-Year Follow-Up Among the Iranian Population. *J Clin Endocrinol Metab*. 2021 Apr 23;106(5):e1968-e1983.
105. Faam B, Ghaffari MA, Khorsandi LS, Ghadiri AA, Totonchi M, Amouzegar A, Fanaei SA, Azizi F, Shahbazian HB , Hashemi Tabar M. RAP1GAP Functions as a Tumor Suppressor Gene and Is Regulated by DNA Methylation in Differentiated Thyroid Cancer. *Cytogenet Genome Res*. 2021 Jul 26;1-9.
106. Birjandi B, Ramezani Tehrani F, Amouzegar A, Tohidi M, Bidhendi Yarandi R, Azizi F. The association between subclinical hypothyroidism and TPOAb positivity with infertility in a population-based study: Tehran thyroid study (TTS). *BMC Endocr Disord*. 2021 May 26;21(1):108.
107. Mahdavi M , Amouzegar A , Mehran L , Madreseh E, Tohidi M, Azizi F. Investigating the prevalence of primary thyroid dysfunction in obese and overweight individuals: Tehran thyroid study. *BMC Endocr Disord*. 2021 Apr 30;21(1):89.
108. Azizi F, Abdi H, Amouzegar A. Control of Graves' hyperthyroidism with very long-term methimazole treatment: a clinical trial. *BMC Endocr Disord*. 2021 Jan 14;21(1):16.
109. Mehran L · Amouzegar A · Abdi H · Delbari N · Madreseh E · Tohidi M · Mansournia M.A · Azizi F. Incidence of Thyroid Dysfunction Facing Metabolic Syndrome: A Prospective Comparative Study with 9 Years of Follow-Up. *Eur Thyroid J* 2021;10:390–398.
110. Kazempour-Ardebili S, Amouzegar A, Tohidi M, Amouzegar A, Azizi F. Prevalence of Subclinical Hypothyroidism in Chronic Kidney Disease in a Population-based Study: Tehran Thyroid Study. *Int J Endocrinol Metab*. 2021 Mar 17;19(2):e103750.
111. Valizadeh M, Farhad Hosseinpanah F, Ramezani Tehrani F, Abdi H, Mehran L, Hadaegh F, Amouzegar A, Sarvghadi F, Azizi F and Iranian Endocrine Society Task Force Iranian Endocrine Society. Iranian Endocrine Society Guidelines for Screening, Diagnosis, and Management of Gestational Diabetes Mellitus. *Int J Endocrinol Metab*. 2021 Jan; 19(1): e107906.

[Type here]

112. Azizi F, Amouzegar A, Abdi H .Efficacy of low-dose methimazole in control of multiple relapses of Graves' hyperthyroidism: a case report. J Med Case Rep. 2021 Apr 23;15(1):189.
113. Ghazi AA, Amouzegar A, Zadeh-Vakili A, Sheikh Rezaei A, Amirbaigloo A, Zarif Yeganeh M, Hashemi H, Azizi F. Clinical and Laboratory Characteristics of a Large Iranian Kindred Afflicted with Von Hippel Lindau Disease. Int J Endocrinol Metab. 2021 Mar 16;19(2):e105189.
114. Nodehi M , Ajami A, Izad M , Asgarian Omran H, Esfahanian F, Yekaninejad S, Hemmatabadi M , Amouzegar A, Chahardoli R , Mansouri F, Saboor-Yaraghi A. The Frequency of CD4+ T Cells in Women with Hashimoto's Thyroiditis. Int J Endocrinol Metab. 2021 Sep 19;19(4):e110013.
115. Amouzegar A, Pearce EN, Mehran L, Lazarus L, Takyar M, Azizi F. TPO antibody in euthyroid pregnant women and cognitive ability in the offspring: a focused review. J Endocrinol Invest. 2021 Sep 13.
116. Abdi H , Faam B , Gharibzadeh S, Mehran L, Tohidi M , Azizi F, Amouzegar A. Determination of age and sex specific TSH and FT4 reference limits in overweight and obese individuals in an iodine-replete region: Tehran Thyroid Study (TTS). Iranian Journal of Endocrinology and Metabolism Endocr Res. 2021 Feb;46(1):37-43.
117. Zahedi M, Hizomi Arani, Rafati M, Amouzegar A, Hadaegh F. Persistent hypercalcemia with similar familial Hypocalciuric hypercalcemia features: a case report and literature review.2021. BMC Endocrine Disorders. 21(1),220
118. Kazemian E, Akbari ME, Moradi N, Gharibzadeh S, Amouzegar A, Rozek LS , Mondul A M, Khademolmele M, Zarins K R, Ghodoosi N , Shateri Z , Fallah S , Davoodi H. Assessment the effect of vitamin D supplementation on plasma vitamin D levels, inflammation, and oxidative stress biomarkers based on vitamin D receptor genetic variation in breast cancer survivors: a protocol for clinical trial. J Health Popul Nutr. 2021 Nov 2;40(1):46.
119. Ghazisaeidi B, Sarvghadi F, Ghasemi A, Tohidi M, Azizi F, Amouzegar A. Association Between Serum Nitric Oxide Level and Changes in Thyroid Function Test in a Population-based Study: Tehran Thyroid Study Participants (TTS). Int J Endocrinol Metab. 2021 Mar 28;19(3):e109214.
120. Mehran L , Shafiee Dolat Abadi S, Amouzegar A, Delshad H, Azizi F. Trimester-Specific Reference Ranges for Free Thyroxine Hormone in Iranian Pregnant Women. Iranian Journal of endocrinology and metabolism. 2021, 23(3): 151-159.(farsi)

[Type here]

## **2022:**

121. Kazemian E , Ansari S , Davoodi S.H, Patterson W.B , Shakerinava P, Wagner C.L , Amouzegar A. The Effect of Maternal Vitamin D Supplementation on Vitamin D Status of Exclusively Breast Feeding Mothers and Their Nursing Infants: A Systematic Review and Meta-analysis of Randomized Clinical Trials. *Adv Nutr*. 2022 Mar;13(2):568-585.
122. Faam B , Ghadiri A.A, Ghaffari M.A, Totonchi M, Amouzegar A, Azizi F, Shahbazian H.B, Hashemitabar M, Fanaei S.A, Khorsandi L. CpG Island Methylation of the Rap1Gap Gene in Medullary Thyroid Cancer. *Arch Iran Med*. 2022;25(3): 171-177.
123. F. Azizi, H. Abdi, L. Mehran, A. Amouzegar. Appropriate duration of antithyroid drug treatment as a predictor for relapse of Graves' disease: a systematic scoping review. *Journal of Endocrinological Investigation*. 2022: 45, 1139–1150.
124. Mehran L, Delbari N, Amouzegar A, Hasheminia M, Tohidi M, Azizi F. Reduced sensitivity to thyroid hormone is associated with diabetes and hypertension. *J Clin Endocrinol Metab*. 2022 Jan 1;107(1):167-176.
125. Kazemian E, Davoodi S.H , Akbari M, Moradi N, Gharibzadeh S, Mondul A.M, Jamshidi-Naeini Y, Khademolmele M, Zarins K.R, Ghodoosi N, Rozek L.S, Amouzegar A. Vitamin D Receptor (VDR) Allelic Variants Correlating with Response to Vitamin D3 Supplementation in Breast Cancer Survivors. *Nutr Cancer*. 2022;74(1):68-81.
126. Mehran L, Amouzegar A, Fanaei S.M, Masoumi S, Azizi F. Anthropometric measures and risk of all-cause and cardiovascular mortality: An 18 years follow-up. *Obes Res Clin Pract*. Jan-Feb 2022;16(1):63-71.
127. Heba Alwan , Fanny Viloz , Martin Feller , Robin P F Dullaart , Stephan J L Bakker , Robin P Peeters , Maryam Kavousi , Douglas C Bauer , Anne R Cappola , Bu B Yeap , John P Walsh , Suzanne J Brown , Graziano Ceresini , Luigi Ferrucci , Jacobijn Gussekloo , Stella Trompet , Massimo Iacoviello , Jae Hoon Moon , Salman Razvi , Isabela M Bensenor , Fereidoun Azizi , Atieh Amouzegar , Sergio Valdés , Natalia Colomo , Nick J Wareham , J Wouter Jukema , Rudi G J Westendorp , Ki Woong Kim , Nicolas Rodondi , Cinzia Del Giovane. Subclinical thyroid dysfunction and incident diabetes: a systematic review and an individual participant data analysis of prospective cohort studies. *Eur J Endocrinol*. 2022 Sep 30;187(5):S35-S46.
128. Azizi F, Saadat N, Takyar MA, Abdi H, Mehran L, Amouzegar A. Efficacy and Safety of Long-Term Methimazole versus Radioactive Iodine in the Treatment of Toxic Multinodular Goiter. *Endocrinol Metab (Seoul)* 2022 Dec; 37(6): 861–869.



[Type here]

129. Ladan Mehran, Pouria Mousapour, Davood Khalili, Leila Cheraghi, Mohammadjavad Honarvar, Atieh Amouzegar, Fereidoun Azizi. BMI variability and incident diabetes mellitus, Tehran Lipid and Glucose Study (TLGS). *Sci Rep.* 2022; 12: 18370. Published online 2022 Nov 1.
130. Azizi F, Saadat N, Abdi H, Mehran L, Masoumi S, Takyar MA, Amouzegar A. Time to Normalization and Sustainable Normal Serum Thyrotropin Concentrations in Patients with Hyperthyroidism: Comparison of Methimazole and Radioactive Iodine Treatments. *Endocrine Practice.* Volume 28, Issue 11, November 2022, Pages 1140-1145.
131. Valizadeh M, Ebadinejad A, Amouzegar A, Zakeri A. Persistent hyperparathyroidism secondary to ectopic parathyroid adenoma in lung: Case report. *Front Endocrinol (Lausanne).* 2022 Dec 13;13:988035.
132. Amouzegar A, Dehghani M, Abdi H, Mehran L, Masoumi S, Azizi F. Natural history of subclinical hypothyroidism and prognostic factors for the development of overt hypothyroidism: Tehran Thyroid Study (TTS). *J Endocrinol Invest.* 2022 Dec;45(12):2353-2364.

[Type here]

## **2023:**

133. Azizi F, Abdi H, Amouzegar A, Habibi Moeini A.S. Long-term thionamide antithyroid treatment of Graves' disease. *Best Practice & Research Clinical Endocrinology & Metabolism*. 2023 Mar;37(2):101631.
134. Amouzegar A, Honarvar M, Masoumi S, Tohidi M, Mehran L, Azizi F. Sex-specific Trajectories of Insulin Resistance Markers and Reduced Renal Function During 18 Years of Follow-up: TLGS. *The Journal of Clinical Endocrinology & Metabolism*, Volume 108, Issue 6, June 2023, Pages e230–e239.
135. Mehran L, Amouzegar A, Foroutan M, Masoumi S, Tohidi M, Abdi H, Ali Aghaei A, Saghafinia A, Azizi F. Pharmacodynamic and pharmacokinetic properties of the combined preparation of levothyroxine plus sustained-release liothyronine; a randomized controlled clinical trial. *BMC Endocr Disord*. 2023; 23: 182. Published online 2023 Aug 28
136. Honarvar M, Masoumi S, Mehran L, Khalili D, Amouzegar A, Azizi F. Development and validation of a continuous metabolic syndrome severity score in the Tehran Lipid and Glucose Study. *Sci Rep*. 2023; 13: 7529. Published online 2023 May 9.
137. Abiri B, Ramezani Ahmadi A, Mahdavi M, Hosseinpanah F, Amouzegar A, Valizadeh M. Association between different metabolic phenotypes and the development of hypothyroidism: 9 years follow-up of Tehran thyroid study. *Front Endocrinol (Lausanne)* 2023; 14: 1134983. Published online 2023 Mar 10.
138. Honarvar M, Mehran L, Masoumi S, Agahi S, Khalili SH, Azizi F, Amouzegar A. Independent association between age- and sex-specific metabolic syndrome severity score and cardiovascular disease and mortality. *Scientific Reports* volume 13, Article number: 14621 (2023)
139. Ghanooni A, Zadeh-Vakili A, Rezvankhah B, Jafari Nodushan S, Akbarzadeh M, Amouzegar A, Daneshpour M, Khalili D, Mehrabi Y, Ebadi SA . Longitudinal Associations Between TPO Gene Variants and Thyroid Peroxidase Antibody Seroconversion in a Population-Based Study: Tehran Thyroid Study. *Genet Test Mol Biomarkers*. 2023 Mar;27(3):65-73.
140. Kazemian E, Madreseh E, Azizi F, Ashrafvand S, Saleh Gargari S, Mansournia MA, Wagner C, Amouzegar A. The association of parathyroid hormone with serum 25-hydroxyvitamin during pregnancy. *J Nutr Sci*. 2023; 12: e1
141. Fanaei M, Mehran L, Amouzegar A, Masoumi S, Amouzegar A, Azizi F. The impact of metabolic syndrome on chronic kidney disease development. Insights from a big prospective study. *Eur J Clin Invest*. 2023 Apr;53(4):e13945.

[Type here]

142. Kabootari M, Habibi Tirtashi R, Zadeh-Vakili A, Zarkesh M, Samadanifard H, Haghghi SH, Azizi F, Amouzegar A. RET/PTC rearrangement in papillary thyroid carcinoma arising in malignant struma ovarii with abdominal wall metastasis and cervical thyroid gland: a case report and review of the literature. *Thyroid Res.* 2023 Sep 27;16(1):39.
143. Azizi F, Abdi H, Mehran L, Perros P, Masoumi S, Amouzegar A. Long-Term Follow-up of Graves Orbitopathy After Treatment With Short- or Long-Term Methimazole or Radioactive Iodine. *Endocrine Practice.* 2023 Apr;29(4):240-246.

[Type here]

## **Publication in Persian Journals:**

### **2007:**

- 1- Amouzegar A, Ordokhani A ,Azizi F. Variation of Urinary Iodine Concentration Within a Month During the First Trimester of Pregnancy in Tehran an Iodine- Repleted Area and Comparison to Non-Pregnant Women. Vol 9 No.1 June 2007. Iranian Journal of Endocrinology & Metabolism

### **2009:**

- 2- Sabet Z, Amouzegar A, Hedayati M, Azizi F. Predicting the Metabolic Syndrome According to Serum Total Testosterone, Free Testosterone Index and SHBG in Males Aged Over 20 Years: Tehran Lipid and Glucose (TLGS). Vol 11, No.4, November 2009. Iranian Journal of Endocrinology & Metabolism.
- 3- Amouzgar A, Mehrabi Y, Hedayati M, Mirmiran P, Vasei M, Delshad H. Goiter and urinary Iodine excretion survey of 8-10 years old school children in Tehran province, 17 years after universal salt iodisation (2007). *Pejouhesh dar Pezeshki*. 2009, 33(1): 13-20.

### **2010:**

- 4- F Azizi, H Delshad , A Amouzegar, M Hedayati, M Hosseini , M Mehraein .Assessment of Iodine Intake in Yazd province; 17 Years after Universal Salt Iodization (The Fourth National Survey: 2007) .JSSU 2010, 18(3): 263-270.

### **2011:**

- 5- Delshad H, Amouzegar A, Salehi F, Azizkhani N, Delshad M, Azizi F .Goiter and Urinary Iodine Excretion Survey of Schoolchildren in Qazvin Provine: Results of 17 Years Universal Salt Iodization in Iran (2007). Vol 13 No.3 September 2011 .Iranian Journal of Endocrinology & Metabolism.
- 6- Fereidon Azizi , Atieh Amouzegar , Hosein Delshad. Diagnosis and treatment of thyrotoxicosis during pregnancy and lactation. *Pajouhandeh*. 2011, 15(6): 234-241.
- 7- Hossein Delshad, Atieh Amouzegar, Saeed Sadeghyan Sharif , Ladan Mehran , Farid Ordokhani Feridoun Azizi. Goiter monitoring of schoolchildren in Kermanshah province; 17 years after salt iodization program. *Journal of Kermanshah University of Medical Sciences*. 2011;15(3)220-226

### **2012:**

- 8- Bahadoran Z , Golzarand M , Mirmiran P , Amouzgar A , Azizi F .Association Between Dietary Phytochemical Index and Occurrence of Metabolic Syndrome and Its Risk Factors (Among Tehranian Adults): Tehran Lipid and Glucose Study. Vol 14 No.4 November 2012 .Iranian Journal of Endocrinology and Metabolism
- 9- Faam B , Amouzegar A , Delshad M , Ghanbarian A , Hossein Panah F , Azizi F. Leisure-Time Physical Activity and its Association with Metabolic Risk Factors in Tehranian Adults: TLGS. Vol 14 No.4 November 2012. Iranian Journal of Endocrinology & Metabolism.

### **2013:**

- 10- Delshad H, Amouzgar A, Mirmiran P, Azizi F .Eighteen Years of Universal Salt Iodization in Iran; The Fourth National Survey of Goiter Prevalence and Urinary Iodine Excretion of Schoolchildren (2007-2008). Vol 15 No.1 May 2013. Iranian Journal of Endocrinology & Metabolism.

[Type here]

11- Fam B, Amouzegar A, Arzhan S, Ghanbariyan A, Delshad M, Hosseinpanah F, Azizi F. Association between Physical Activity and Metabolic Risk Factors in Adolescents: Tehran Lipid and Glucose Study. *Int J Prev Med*. 2013 Sep; 4(9):1011-7.

12- Azizi F , Delshad H , Amouzegar A , Mehran L , Mirmiran P , Sheikholeslam R. Marked Reduction in Goiter Prevalence and Eventual Normalization of Urinary Iodine Concentrations in Iranian Schoolchildren, 10 Years After Universal Salt Iodination

**2014:**

13- Amiri P, Amouzegar A, Gharibzadeh S, Kazemian E, Ramezani Tehrani F, Azizi F. Socio-behavioral and reproductive determinants associated with contraceptive method choice among Tehranian women: Tehran Lipid and Glucose Study. *Pejouhesh dar Pezeshki*. 2014, 38(2): 111-119.

14- L Mehran, M Delshad, A Amouzegar, Hasheminia M, H Delshad, F Azizi. Does serum TSH Thyrotropin within normal range in associated with body mass index? *Iranian Journal of Endocrinology & Metabolism*.

15- L Mehran, G Amirshakari, A Amouzegar, M Hasheminia, H Delshad, F Azizi. Smoking, thyroid function and thyroxine index antibody. *Iranian Journal of Endocrinology & Metabolism*.

16- Ramezani Tehrani F , Zadeh Vakili A, Hashemi S , Amouzegar A , Azizi F. Associations Between Hormonal Profiles of Urban Iranian Women of Reproductive age: A Community Based Study of Four Provinces. *Iranian Journal of Endocrinology & Metabolism*. Vol 14 No.1 May 2012.

17- Azizi F, Delshad H, Amouzegar A, Mehran L, Mirmiran P, Zahedi Asl S. Prevention of Iodine-deficiency Induced Goiter and Brain Damage in the Islamic Republic of Iran. *Iranian Journal of Endocrinology and Metabolism*. Vol 15 No.5 January 2014

18- Azizi F, Delshad H, Amouzegar A, Mehran L, Mirmiran P, Sheikholeslam R, Naghavi M, Ordookhani A, Hedayati M, Padyab M. Marked Reduction in Goiter Prevalence and Eventual Normalization of Urinary Iodine Concentrations in Iranian Schoolchildren, 10 Years After Universal Salt Iodination (Third National Survey of Iodine Deficiency Disorders 2000)

**2015:**

19- Sadatamini M, Delshad H, Amouzegar A, Tohidi M, Azizi F. The Incidence of Thyroid Dysfunctions in Patients with Type 2 Diabetes: a Twelve-year Follow-up of the Tehran Lipid and Glucose Study. *Iranian Journal of Endocrinology and Metabolism*. Vol 17 No.1 April-May 2015.

**2016:**

20- HamzaviZarghani N, Ghofranipour F, Amiri P, Amouzegar A, Nazeri P, Hedayati M, Mirmiran P, Azizi F . Iodine Intake Knowledge, Attitude and Practice in Pregnant Women and its Relation to Iodine Status during Pregnancy. *Iranian Journal of Endocrinology and Metabolism*. Vol 17 No.6 February-March 2016.

21- Hosseini M, Amouzegar A, tohidi M, Tahmasebinejad ZH, Dr. fereidoun azizi. Prevalence and Incidence of Thyroid Dysfunction in Individuals Aged Over 55 Years (Tehran Thyroid Study). *Iranian Journal of Endocrinology and Metabolism*. Vol 18 No.3 2016.

22- Clinical guidelines for the diagnosis and treatment of thyroid disorders during pregnancy and postpartum (Iran Endocrine Society). *IJEM* Vol 18, 3 (serial number 87), Aug –Sep 2016 (FARSI version for Iranian clinicians).

[Type here]

**2018:**

- 23- Aidin Baghbani-Oskouei, Samaneh Akbarpour, Maryam Tohidi , Atieh Amouzegar , Ladan Mehran, Farzad Hadaegh, Fereidoun Azizi. Subclinical Thyroid Dysfunction and Incident Cardiovascular Disease: Tehran Thyroid Study. Iranian Journal of Endocrinology and Metabolism. Vol 20 No.1 2018.

**Chapters, Books:( *List of chapters or published books according to Vancouver style, from past to present*)**

- Azizi F, Tehrani FR. Thyroid Diseases in Pregnancy. Springer; 2022.
- Epidemiology and Control of Common Diseases in Iran (In Persian)
- Analysis of Treatment Intent and Composite Outcome(In Persian)
- Comprehensive Book on Fasting and Health(In Persian)

-